Literature DB >> 11448026

Comparative analysis of host responses related to immunosuppression between measles patients and vaccine recipients with live attenuated measles vaccines.

H Okada1, T A Sato, A Katayama, K Higuchi, K Shichijo, T Tsuchiya, N Takayama, Y Takeuchi, T Abe, N Okabe, M Tashiro.   

Abstract

Measles virus infection induces a profound immunosuppression. We analyzed in a time-dependent manner peripheral bloods of one to two-year-old children immunized with live attenuated measles vaccines, compared with age-matched measles patients, for immunosuppression. In contrast to transient severe lymphopenia with measles patients, primarily due to extensive apoptosis of a broad spectrum of uninfected lymphocytes, neither apoptosis nor lymphopenia occurred with measles vaccine recipients. Increase in number and activation of NK cells, which might compensate for the lymphopenia in measles patients, were not found with the vaccinees. While cell surface expression of apoptosis-related molecules such as TNF-related apoptosis-inducing ligand (TRAIL), TRAIL-receptors, CD95(Fas) and Fas-ligand, and plasma interferon-gamma were increased for measles patients, they remained unchanged after vaccination. Plasma interleukin (IL)-18, which is responsible for inducing apoptosis in several infectious diseases, was increased predominantly with measles patients, whereas the increase remained marginal with the vaccinees. IL-10 was elevated transiently in both measles patients and vaccinees. Decrease in plasma IL-12, which is often correlated with T cell suppression, was not found for both cases. Serum IgM and IgG antibodies to measles virus were induced at lower titers in the vaccinees than measles patients. These results indicate that in contrast to wild-type measles virus, live measles vaccines hardly provoked host cytokine responses that lead to apoptotic cytolysis of uninfected lymphocytes, lymphopenia and immunosuppression, and thereby induced weaker immune responses to the virus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11448026     DOI: 10.1007/s007050170121

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  19 in total

1.  Oncolytic measles virus expressing the sodium iodide symporter to treat drug-resistant ovarian cancer.

Authors:  Evanthia Galanis; Pamela J Atherton; Matthew J Maurer; Keith L Knutson; Sean C Dowdy; William A Cliby; Paul Haluska; Harry J Long; Ann Oberg; Ileana Aderca; Matthew S Block; Jamie Bakkum-Gamez; Mark J Federspiel; Stephen J Russell; Kimberly R Kalli; Gary Keeney; Kah Whye Peng; Lynn C Hartmann
Journal:  Cancer Res       Date:  2014-11-14       Impact factor: 12.701

2.  Measles virus (MV) nucleoprotein binds to a novel cell surface receptor distinct from FcgammaRII via its C-terminal domain: role in MV-induced immunosuppression.

Authors:  David Laine; Marie-Claude Trescol-Biémont; Sonia Longhi; Geneviève Libeau; Julien C Marie; Pierre-Olivier Vidalain; Olga Azocar; Adama Diallo; Bruno Canard; Chantal Rabourdin-Combe; Hélène Valentin
Journal:  J Virol       Date:  2003-11       Impact factor: 5.103

3.  MMR Vaccine and Covid-19: A Myth or a Low Risk-High Reward Preventive Measure?

Authors:  Sanjay Deshpande; Sarath Balaji
Journal:  Indian Pediatr       Date:  2020-07-24       Impact factor: 1.411

4.  Canine distemper virus epithelial cell infection is required for clinical disease but not for immunosuppression.

Authors:  Bevan Sawatsky; Xiao-Xiang Wong; Sarah Hinkelmann; Roberto Cattaneo; Veronika von Messling
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

5.  Safety and immunogenicity of early measles vaccination in children born to HIV-infected mothers in the United States: results of Pediatric AIDS Clinical Trials Group (PACTG) protocol 225.

Authors:  Sulachni Chandwani; Judy Beeler; Hong Li; Susette Audet; Betsy Smith; John Moye; David Nalin; Keith Krasinski
Journal:  J Infect Dis       Date:  2011-07       Impact factor: 5.226

Review 6.  Measles Vaccine.

Authors:  Diane E Griffin
Journal:  Viral Immunol       Date:  2017-12-19       Impact factor: 2.257

Review 7.  Measles virus-induced immunosuppression: from effectors to mechanisms.

Authors:  Elita Avota; Evelyn Gassert; Sibylle Schneider-Schaulies
Journal:  Med Microbiol Immunol       Date:  2010-04-08       Impact factor: 3.402

8.  Functional and phenotypic changes in circulating lymphocytes from hospitalized zambian children with measles.

Authors:  Judith J Ryon; William J Moss; Mwaka Monze; Diane E Griffin
Journal:  Clin Diagn Lab Immunol       Date:  2002-09

9.  HIV RNA suppression among HIV-infected Ugandan children with measles.

Authors:  Theodore D Ruel; Jane Achan; Anne F Gasasira; Edwin D Charlebois; Tsedal Mehbratu; Philip J Rosenthal; Grant Dorsey; Moses R Kamya; Adeodata Kekitiinwa; Joseph Wong; Diane V Havlir
Journal:  J Acquir Immune Defic Syndr       Date:  2008-06-01       Impact factor: 3.731

10.  Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide.

Authors:  R M Myers; S M Greiner; M E Harvey; G Griesmann; M J Kuffel; S A Buhrow; J M Reid; M Federspiel; M M Ames; D Dingli; K Schweikart; A Welch; A Dispenzieri; K-W Peng; S J Russell
Journal:  Clin Pharmacol Ther       Date:  2007-10-31       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.